Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Lancet Psychiatry ; 8(3): 215-224, 2021 03.
Article in English | MEDLINE | ID: mdl-33600749

ABSTRACT

BACKGROUND: No consistent first-option psychological interventions for adult outpatients with anorexia nervosa emerges from guidelines. We aimed to compare stand-alone psychological interventions for adult outpatients with anorexia nervosa with a specific focus on body-mass index, eating disorder symptoms, and all-cause dropout rate. METHODS: In this systematic review and network meta-analysis, we assessed randomised controlled trials about stand-alone pharmacological or non-pharmacological treatments of adult outpatients with anorexia nervosa, defined according to standardised criteria, with data for at least two timepoints relating to either body-mass index or global eating disorder psychopathology. We searched Cochrane CENTRAL, CINAHL, MEDLINE, and PsychINFO for published and unpublished literature from inception until March 20, 2020. The primary outcomes were the change in body mass index and clinical symptoms, and the secondary outcome was all-cause dropout rate, which were all assessed for treatment as usual, cognitive behavioural therapy (CBT), Maudsley anorexia treatment for adults, family-based treatment, psychodynamic-oriented psychotherapies, a form of CBT targeting compulsive exercise, and cognitive remediation therapy followed by CBT. Global and local inconsistencies for the network meta-analysis were measured, and CINeMA was used to assess the confidence in evidence for primary outcomes. The protocol is registered in PROSPERO (CRD42017064429). FINDINGS: Of 14 003 studies assessed for their title and abstract, 16 (0·1%) randomised controlled trials for psychological treatments were included in the systematic review, of which 13 (0·1%) contributed to the network meta-analysis, with 1047 patients in total (of whom 1020 [97·4%] were female). None of the interventions outperformed treatment as usual in our primary outcomes, but the all-cause dropout rate was lower for CBT than for psychodynamic-oriented psychotherapies (OR 0·54, 95% CI 0·31-0·93). Heterogeneity or inconsistency emerged only for a few comparisons. Confidence in the evidence was low to very low. INTERPRETATION: Compared with treatment as usual, specific psychological treatments for adult outpatients with anorexia nervosa can be associated with modest improvements in terms of clinical course and quality of life, but no reliable evidence supports clear superiority or inferiority of the specific treatments that are recommended by clinical guidelines internationally. Our analysis is based on the best data from existing clinical studies, but these findings should not be seen as definitive or universally applicable. There is an urgent need to fund new research to develop and improve therapies for adults with anorexia nervosa. Meanwhile, to better understand the effects of available treatments, participant-level data should be made freely accessible to researchers to eventually identify whether specific subgroups of patients are more likely to respond to specific treatments. FUNDING: Flinders University, National Institute for Health Research Oxford Health Biomedical Research Centre.


Subject(s)
Anorexia Nervosa/therapy , Psychosocial Intervention/methods , Adult , Anorexia Nervosa/psychology , Body Mass Index , Humans , Network Meta-Analysis , Outpatients , Quality of Life , Randomized Controlled Trials as Topic , Treatment Outcome
2.
AJNR Am J Neuroradiol ; 41(6): 1001-1008, 2020 06.
Article in English | MEDLINE | ID: mdl-32439639

ABSTRACT

BACKGROUND AND PURPOSE: Previous studies have suggested that the central vein sign and iron rims are specific features of MS lesions. Using 3T SWI, we aimed to compare the frequency of lesions with central veins and iron rims in patients with clinically isolated syndrome and MS-mimicking disorders and test their diagnostic value in predicting conversion from clinically isolated syndrome to MS. MATERIALS AND METHODS: For each patient, we calculated the number of brain lesions with central veins and iron rims. We then identified a simple rule involving an absolute number of lesions with central veins and iron rims to predict conversion from clinically isolated syndrome to MS. Additionally, we tested the diagnostic performance of central veins and iron rims when combined with evidence of dissemination in space. RESULTS: We included 112 patients with clinically isolated syndrome and 35 patients with MS-mimicking conditions. At follow-up, 94 patients with clinically isolated syndrome developed MS according to the 2017 McDonald criteria. Patients with clinically isolated syndrome had a median of 2 central veins (range, 0-19), while the non-MS group had a median of 1 central vein (range, 0-6). Fifty-six percent of patients who developed MS had ≥1 iron rim, and none of the patients without MS had iron rims. The sensitivity and specificity of finding ≥3 central veins and/or ≥1 iron rim were 70% and 86%, respectively. In combination with evidence of dissemination in space, the 2 imaging markers had higher specificity than dissemination in space and positive findings of oligoclonal bands currently used to support the diagnosis of MS. CONCLUSIONS: A single 3T SWI scan offers valuable diagnostic information, which has the potential to prevent MS misdiagnosis.


Subject(s)
Brain/diagnostic imaging , Demyelinating Diseases/diagnostic imaging , Multiple Sclerosis/diagnostic imaging , Neuroimaging/methods , Adult , Aged , Brain/pathology , Demyelinating Diseases/pathology , Female , Humans , Image Interpretation, Computer-Assisted , Magnetic Resonance Imaging/methods , Male , Middle Aged , Multiple Sclerosis/pathology , Sensitivity and Specificity , Young Adult
3.
Acta Psychiatr Scand ; 140(2): 116-125, 2019 08.
Article in English | MEDLINE | ID: mdl-31111467

ABSTRACT

OBJECTIVE: Several depressed patients do not respond to traditional antidepressants. Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression. METHODS: We conducted a systematic review of randomized clinical trials (RCTs) and observational studies on pramipexole for patients with major depressive episodes, following PRISMA guidelines. Our primary outcome measure was treatment response at endpoint. The study protocol was registered on PROSPERO: CRD42018108699. RESULTS: We found five RCTs, three open-label trials and five observational studies, with 504 participants (57% women; mean age, 45.3 years; mean sample size, 39; median duration of treatment, 8 weeks; mean follow-up duration, 45 weeks; mean maximum dose, 1.62 mg). We found an overall short-term response rate of 52.2% and remission rate of 36.1%, and an overall long-term response rate of 62.1% and remission rate of 39.6%. In RCTs, patients treated with pramipexole had a superior response rate compared with placebo (RR: 1.77; 95% CI: 1.11-2.82) and similar to SSRIs (RR: 0.93; 95% CI: 0.44-1.95). Acceptability and tolerability were good, with nausea being the most frequent side-effect. CONCLUSION: Our study found some evidence for an effect of pramipexole for the treatment of major depressive episodes.


Subject(s)
Bipolar Disorder/drug therapy , Depressive Disorder, Major/drug therapy , Dopamine Agonists/therapeutic use , Pramipexole/therapeutic use , Adolescent , Adult , Aged , Bipolar Disorder/epidemiology , Bipolar Disorder/psychology , Case-Control Studies , Depressive Disorder, Major/epidemiology , Depressive Disorder, Major/psychology , Dopamine Agonists/adverse effects , Female , Humans , Male , Middle Aged , Observational Studies as Topic , Placebos/administration & dosage , Pramipexole/adverse effects , Randomized Controlled Trials as Topic , Remission Induction , Selective Serotonin Reuptake Inhibitors/therapeutic use , Treatment Outcome , Young Adult
4.
Mult Scler Relat Disord ; 27: 305-311, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30453199

ABSTRACT

INTRODUCTION: In this two year longitudinal study we compare the progression of grey matter (GM) damage in MS patients treated with glatiramer acetate (GA) for relapsing-remitting multiple sclerosis (RRMS) respect to untreated patients. METHODS: We studied thirty-five treated with GA and thirty-five untreated RRMS subjects matched for age, gender, disease duration and EDSS. Each patient underwent neurological examination every 6 months and 3-Tesla MRI at study entry (T0), after 1 year (T1) and 2 years (T2). At T0, T1 and T2, the number of new cortical lesions (CLs) was assessed on double inversion recovery images. By using the longitudinal stream of FreeSurfer, the cortical thickness and volume changes of several cerebral structures were evaluated after 2 years. RESULTS: The mean number of new CLs was significantly lower in GA group compared to untreated patients both at T1 (0.9 ±â€¯1.0 vs 1.7 ±â€¯1.0, p < 0.05) and at T2 (1.4 ±â€¯1.3 vs 2.9 ±â€¯1.8, p < 0.001). Volume loss of thalamus (-0.5% ±â€¯0.2% vs. -1.1% ±â€¯0.4%; p < 0.001), globus pallidus (-4.4% ±â€¯3.1% vs. -8.2% ±â€¯4.5%; p < 0.001), hippocampus (-0.7% ±â€¯0.3% vs. -1.5% ±â€¯0.5%; p < 0.001) and cerebellum (-0.5% ±â€¯0.3% vs. -0.9% ±â€¯0.4%; p < 0.001) was also lower in the GA group. A more pronounced cortical thinning was observed in cingulate (p = 0.04), cuneus and frontomarginal gyrus (p = 0.01 for both comparisons) of the untreated patients. CONCLUSION: Our findings suggest that GA exerts its immunomodulatory action at the level of GM either reducing the accumulation of CLs and slowing down the GM atrophy progression. Despite a confirmation in a larger sample size is required, our results suggest a possible effect of GA on GM damage.


Subject(s)
Cerebral Cortex/drug effects , Cerebral Cortex/pathology , Glatiramer Acetate/therapeutic use , Gray Matter/drug effects , Gray Matter/pathology , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/pathology , Neuroprotective Agents/therapeutic use , Adolescent , Adult , Cerebral Cortex/diagnostic imaging , Disease Progression , Female , Gray Matter/diagnostic imaging , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging , Treatment Outcome , Young Adult
5.
Acta Psychiatr Scand ; 136(6): 549-558, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28612993

ABSTRACT

OBJECTIVE: Melatonin has been widely studied in the treatment of sleep disorders and evidence is accumulating on a possible role for melatonin influencing mood. Our aim was to determine the efficacy and acceptability of melatonin for mood disorders. METHOD: We conducted a comprehensive systematic review of randomized clinical trials on patients with mood disorders, comparing melatonin to placebo. RESULTS: Eight clinical trials were included; one study in bipolar, three in unipolar depression and four in seasonal affective disorder. We have only a small study on patients with bipolar disorder, while we have more studies testing melatonin as an augmentation strategy for depressive episodes in major depressive disorder and seasonal affective disorder. The acceptability and tolerability were good. We analyzed data from three trials on depressive episodes and found that the evidence for an effect of melatonin in improving mood symptoms is not significant (SMD = 0.37; 95% CI [-0.05, 0.37]; P = 0.09). The small sample size and the differences in methodology of the trials suggest that our results are based on data deriving from investigations occurring early in this field of study. CONCLUSION: There is no evidence for an effect of melatonin on mood disorders, but the results are not conclusive and justify further research.


Subject(s)
Central Nervous System Depressants/therapeutic use , Melatonin/therapeutic use , Mood Disorders/drug therapy , Humans , Treatment Outcome
6.
Psychol Med ; 45(5): 897-910, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25126858

ABSTRACT

BACKGROUND: Individuals with autism spectrum disorders (ASDs) are characterized by social communication difficulties and behavioural rigidity. Difficulties in learning from others are one of the most devastating features of this group of conditions. Nevertheless, the nature of learning difficulties in ASDs is still unclear. Given the relevance of implicit learning for social and communicative functioning, a link has been hypothesized between ASDs and implicit learning deficit. However, studies that have employed formal testing of implicit learning in ASDs provided mixed results. METHOD: We undertook a systematic search of studies that examined implicit learning in ASDs using serial reaction time (SRT), alternating serial reaction time (ASRT), pursuit rotor (PR), and contextual cueing (CC) tasks, and synthesized the data using meta-analysis. A total of 11 studies were identified, representing data from 407 individuals with ASDs and typically developing comparison participants. RESULTS: The results indicate that individuals with ASDs do not differ in any task considered [SRT and ASRT task: standardized mean difference (SMD) -0.18, 95% confidence interval (CI) -0.71 to 0.36; PR task: SMD -0.34, 95% CI -1.04 to 0.36; CC task: SMD 0.27, 95% CI -0.07 to 0.60]. CONCLUSIONS: Based on our synthesis of the existing literature, we conclude that individuals with ASDs can learn implicitly, supporting the hypothesis that implicit learning deficits do not represent a core feature in ASDs.


Subject(s)
Autism Spectrum Disorder/psychology , Learning Disabilities/psychology , Learning/physiology , Autism Spectrum Disorder/physiopathology , Cues , Humans , Learning Disabilities/physiopathology , Neuropsychological Tests , Reaction Time , Serial Learning
7.
J Cardiovasc Surg (Torino) ; 55(5): 679-83, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25008058

ABSTRACT

AIM: Dilation of one or both common iliac arteries (CIAs) is a major concern in endovascular aneurysm repair (EVAR). One option for CIA aneurysm repair is hypogastric embolization followed by endograft extension into the external iliac artery. However, hypogastric occlusion does not always go unpunished and it may lead to ischemic complications. Aim of the paper was to evaluate early results with the Gore® Excluder® Iliac Branch Endoprosthesis (IBE) in the treatment of iliac aneurysms associated or not with abdominal aortic aneurysms. METHODS: Between November 2013 and April 2014, in our Institution 7 Gore IBE were implanted in 5 patients. Technical success, 30-day mortality and complications were investigated. RESULTS: Technical success and branch patency was 100%. There was no 30-day mortality. In 1 of the 2 bilateral cases an endovascular relining with bare stents was required due to a compression of iliac legs at level of aortic bifurcation. CONCLUSION: Use of Gore IBE device in the treatment of aorto-iliac disease is feasible and safe. Late results are necessary to evaluate the performance of this endograft in the long term.


Subject(s)
Blood Vessel Prosthesis Implantation/instrumentation , Blood Vessel Prosthesis , Endovascular Procedures/instrumentation , Iliac Aneurysm/surgery , Stents , Aged , Aortography , Blood Vessel Prosthesis Implantation/adverse effects , Endovascular Procedures/adverse effects , Humans , Iliac Aneurysm/diagnosis , Iliac Aneurysm/physiopathology , Male , Middle Aged , Prosthesis Design , Rome , Time Factors , Treatment Outcome , Vascular Patency
SELECTION OF CITATIONS
SEARCH DETAIL
...